Ann: Cellmid to Commence Selling of Evolis into Chinese Market, page-15

Represents a significant milestone for évolis® and the first step to bringing a unique and differentiated product range to the world's fastest growing market

Beijing Fukangren, established in 2000, is a rapidly growing pharmaceutical company with over 400 staff, distributing over 300 products including generics and drugs under licence and profit arrangement. Fukangren is a full pipeline company, performing basic research, drug development for small molecules and biologics, formulation, manufacture (generic, traditional and novel drugs) and clinical research. The Company’s R&D unit is one of the largest in China and is led by CSO, Professor Zhao Kang, who was the former CSO of international pharmaceutical company, Novartis. Fukangren also has a specialist regulatory affairs team with a strong track record of successful applications with the Chinese regulator, SFDA. The Company is currently in preparation for its IPO, scheduled for later in CY2018. Fukangren’s CEO Mr Jinjing Wang said: “Given our distribution capacity and customer reach, we are excited to take a unique and effective product like évolis® to market through our pharmacy channels in China”.